In recent years, Immune Checkpoint Inhibitors (ICIs) particularly those targeting Programmed Death 1 (PD-1) and PD-L1, have emerged as promising options for the treatment of various cancers, including NPC (18). This evidence concerns the gene CD274 and cancer.